Vertex PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | Filled prescriptions (approx) |
|---|---|
| Q2 2026 | 535,000 |
| 1H 2026 | 900,000 |
| Asset | Printed status | Setting |
|---|---|---|
| Povetacicept | PDUFA date November 30, 2026 | IgA nephropathy launch prep |
| Crinetics Pharmaceuticals | Acquisition agreement; close anticipated Q3 2026, not in FY 2026 guidance | Rare endocrine diseases as a fifth pillar |
| ALYFTREK ages 2 to 5 | Phase 3 data; global regulatory submissions initiated | 65% of children in the study reached sweat chloride under 30 mmol/L |
| CASGEVY ages 2 and older | U.S. FDA approved in children 2+ for SCD or TDT | About 5,500 additional eligible patients at the print date |